Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
396. |
ECCT/14/09/02 | LIVING STUDY-PHASE III B. Prospective study of Lopinavir based ART for HIVInfected childreNGlobally (LIVING study) |
Principal Investigator(s) 1. Elizabeth Maleche Obimbo 2. Elizabeth Bukusi 3. Winstone Nyandiko 4. Bienvenu Baruani Ngoy 5. Joseph Kariuki Mbuthia 6. Allan Godfrey Otieno 7. Lucy Koech 8. Neema Mturi 9. Beatrice Mutai Site(s) in Kenya 1. University of Nairobi/ Kenyatta National Hospital (Nairobi City county) 2. AMPATH, Moi University Teaching and Referral Hospital Eldoret (Uasin Gishu county) 3. MSF Belgium Kibera Clinic (Nairobi City county) 4. Gertrude\'s Children\'s Hospital (Nairobi City county) 5. Mbagathi District Hospital (Nairobi City county) |
View |
397. |
ECCT/14/09/01 | Extension to study MALARIA-055 PRI (110021) for evaluation of long-term efficacy, safety and immunogenicity of GSK Biologicals’candidate malaria vaccine (SB257049) in infants and children in Africa An open extension to the phase III, multi-center study MALARIA-055 PRI (110021) to evaluate long-term efficacy, safety and immunogenicity of the RTS,S/AS01E candidate vaccine against malaria disease caused by Plasmodium falciparum in infants and children in Africa. Study number: MALARIA-076 (200599) |
Principal Investigator(s) 1. Walter Otieno Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project |
View |
398. |
ECCT/14/08/05 | Brief Bactericidal Activity of Anti TB drugs Brief Bactericidal Activity of Anti-Tuberculosis Drugs |
Principal Investigator(s) 1. Videlis Nzioka Nduba Site(s) in Kenya KEMRI-CGHR |
View |
399. |
ECCT/14/08/03 | STAND Study (Shortening Treatment by Advancing Novel Drugs) Long Title: A Phase 3 Open Label Partially Randomised Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin plus PA-824 plus Pyrazinamide after 4 and 6 months of Treatment in Adult Subjects with Drug Sensitive Smear Positive Pulmonary Tuberculosis and after 6 months of Treatment in Adult Subjects with Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis Short Title: STAND Study (Shortening Treatment by Advancing Novel Drugs) |
Principal Investigator(s) 1. Dr Videlis Nduba 2. Dr Evans Amukoye Site(s) in Kenya 1. KEMRI-CRDR(East Nairobi) (Nairobi City county) 2. KEMRI-CRDR(West Nairobi) (Nairobi City county) |
View |
400. |
ECCT/14/08/02 | A5288 Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE) |
Principal Investigator(s) 1. ESTHER MUMBI MAKANGA Site(s) in Kenya KEMRI/CDC CLINICAL RESEARCH CENTRE |
View |